Table 3.
Therapeutic efficacy of AM and AL at days 28, 42 and 63 in adult patients in Senegal – IIT and PP analysis
| Outcome | Artesunate Mefloquine (n = 157) | Artemether Lumefantrine (n = 153) | p value |
|---|---|---|---|
| Intention to treat analysis |
|
|
|
| Early treatment failure |
00 |
00 |
- |
| NA |
6 (3.82%) |
4 (2.61%) |
0.77 |
| Crude Parasitological failure at day 28 |
1 (0.64%) |
4 (2.61%) |
0.35 |
| PCR adjusted failure rate |
1 (0.64%) |
1 (0.65%) |
|
| PCR adjusted cure rate at day 28 |
150 (95.54%) |
148 (96.73%) |
0.58 |
| |
Artesunate Mefloquine |
Artemether Lumefantrine |
|
| Per protocol analysis |
|
|
|
| Early treatment failure |
00 |
00 |
- |
| Crude parasitological failure |
1/151 (0.66%) |
4/149 (2.6%) |
0.17 |
| PCR adjusted failure rate |
1/151 (0.66%) |
1/149 (0.67%) |
0.99 |
| PCR adjusted cure rate at day 28 |
150/151 (99.34%) |
148/149 (99.33%) |
0.99 |
| Crude parasitological failure at day 42 |
2/70 (2.8%) |
5/57 (8.7% |
0.20 |
| PCR adjusted ACPR at day 42 |
69/70 (98.5%) |
56/57 (98.2%) |
1 |
| Crude parasitological failure at day 63 |
4/57 (7%) |
6/44 (13%) |
0.32 |
| PCR adjusted ACPR at day 63 | 56/57 (98.2%) | 43/44 (97.7%) | 1 |
NA = Not applicable.